Skip to main content
World Congress on Medical Oncology
Olympic Paris 2024
Test 4
Test 1
Test 2
Test 5
Test 3
Test clone mv
Olympic Paris 2024
Olympic Paris 2024 - VIP - Boss Ticket
Olympic Paris 2024
Finance Code Test
Concrete Institute of Australia’s Biennial National Conference 2025
Concrete Institute of Australia’s Biennial National Conference 2025
Test Goldenowl Conference
Virtual Event 01
Paris Olypmpic Clone 12.09 webinar
7th World Congress of Nanoentomology
NDS NAB Transact testing
JC test 01
Pre-Release 3 Oct
DEX (Digital Employee Experience) conference 2024
test derek
TimeZone Test
TimeZone Test
Talent Events
Event Demo
Olympic Paris 2024 x
original event name for cloning testing
Olympic Paris 2024
Default payment method test
evexus Event - 509
Default payment method test2
Test Worker
Test Worker
charlie test
Arinex 1
NET24 Ho Chi Minh City Workshop 2024
Telefilm 2024 - International Exhibition of Film and Television Technology in Vietnam
Olympic Paris 2024
charlie test 2711
charlie test 2711 cloned
CICM SecurePay testing
The AI Submit 2024
Test webinar 04.12 - - - -
Taylor Swift Clone 04
Taylor Swift Clone 02
Taylor Swift
Taylor Swift Clone
Taylor Swift Clone 01
Import Test
The Trading Summit 2024 (HCM - Vietnam)
Electric Dreams: A Synthwave Extravaganza
Taylor Swift 16
Taylor Swift 12
Taylor Swift 14
Taylor Swift 15
Taylor Swift 17
Taylor Swift 20
Coin Based Hackathon 2024
Rose 01
Import Ticket
Vu Cat Tuong
STEM 1
Kids STEM
CLONE Innovate 2025: A Future Forward Summit
Innovate 2025: A Future Forward Summit
Petals & Sunshine Festival
webinar 05/02
Science
evexus Event - 273
evexus Event - 275
Association webinar 5.2
evexus Event - 274
Aurora Nights 2025 - Webinar
Seoul AI Seminar
Webinar Event - Lily AI - 20/02
evexus Event - 287
Taylor Swift 11
Swifties Only Social Contact
cloned event for Bree QA
evexus Event - 288
evexus Event - 289
Bree QA event
Tim's event
Ralph's event
Tim cloned enable all
Ralph clone event the last one
Hawaii AI Seminar
evexus Event - 293
Tokyo Seminar
Indiana AI Seminar
Registration ticket 2025
TechNova Summit
Event - 28 - 03 - 2025
TechNova Summit [2]
TechNova Summit [3]
Tech v1
Event 28/03/2025
Job Affairs
Fan Job
Webinar Event - Lily AI - 04/03
Event Registration
Association webinar 20.2
Fan's stock query
Registration
Aurora Nights 2025
Ralph test email
Taylor Swift 13
The Core 2025
Rose
The Thirdweb submit
Stress Test Conference 2026
Alan'event
World Congress of Medical Oncology
The AI Seoul Submit 2026
The Core 2026
Times are shown in your local time zone GMT
Take a PUNT on PLUNT – incorporating lymphovascular invasion to produce a more robust tool for recurrence risk in node-negative NSCLC patients.
Verbal Presentation

Verbal Presentation

4:12 pm

03 May 2026

Meeting Room M1

Cardiothoracic - Research Papers

Talk Description

Institution: Royal Hobart Hospital - Tasmania, Australia

Background: There is a major deficiency of a national comprehensive thoracic oncology surgery data especially in regional and remote areas such as Tasmania1. Unique to this region is its large proportion of elderly persons. The PUNT score utilises high risk features of pleural involvement, unassignable histology, neutrophil-to-lymphocyte ratio (NLR) >3.5 and tumour size to help identify patients with node-negative NSCLC at significantly discordant risk of recurrence to their TNM staging. Lymphovascular invasion, a risk factor for recurrence, was not incorporated in this score. Methods: This retrospective analysis examined all thoracic oncology cases undergoing surgical resection at Royal Hobart Hospital (2010-2022). A subgroup analysis was done on elderly node-negative lung cancer patients. We developed the PLUNT scoring system, incorporating lymphovascular invasion into the established PUNT framework, and compared prognostic performance using Cox proportional hazards regression and Kaplan-Meier survival analysis. Results: Eighty-six elderly patients with node-negative NSCLC were analysed using the PUNT and PLUNT scoring (mean age 75.2 years, 51.2% male). PLUNT > 2.0 identified 12 high-risk patients (14.0%) with 33.3% recurrence rate, while PUNT > 1.5 identified 10 patients (11.6%) with 30.0% recurrence rate. In multivariate analysis, PLUNT > 2.0 achieved statistical significance as an independent predictor of recurrence-free survival (HR = 3.700, 95% CI: 1.033-13.252, p = 0.0456), while PUNT > 1.5 failed to reach significance (p = 0.1609). Conclusions: PLUNT scoring demonstrates superior prognostic performance over PUNT thus providing enhanced risk stratification crucial for clinical decision-making. The incorporation of lymphovascular invasion significantly improves prognostic accuracy, supporting personalized treatment approaches such as the potential role in adjuvant therapy for high-risk patients.
Speakers
Contributors
Authors

Dr Ayeshmanthe Rathnayake - , Mr Ashutosh Hardikar -

Other Suggested Talks
Privacy Statement Header

By confirming your acceptance below, you agree to our Privacy Policy